在大型生物样本库数据集中评估已发表前列腺癌多基因风险评分的临床效用
本病例对照研究从多基因评分目录下载16个已发表的前列腺癌多基因风险评分(PRS),应用于密歇根基因组学倡议(MGI)患者,并与MUSIC登记处匹配获取临床病理数据。共纳入18050例患者(2740例前列腺癌病例,15310例对照)。PRS预测前列腺癌发病风险的协变量校正AUC范围为0.51(95%CI 0.51-0.53)至0.67(95%CI 0.66-0.68),但PRS与疾病侵袭性无关联。
要点
- 16个已发表PRS预测前列腺癌发病风险的aAUC范围为0.51至0.67。
- PRS与前列腺癌疾病侵袭性之间无关联。
- PRS在识别前列腺癌高风险男性方面具有中等真实世界性能,但区分惰性与侵袭性疾病能力有限。
核心结论
- 前列腺癌PRS在识别发病高风险患者方面具有中等真实世界性能,但在区分惰性与侵袭性疾病方面能力有限。
研究设计与样本
- 病例对照研究,从多基因评分目录下载16个已发表PRS(下载日期2021年5月28日),应用于MGI患者,病例与MUSIC登记处匹配获取临床病理数据。
- MGI前瞻性纳入在密歇根大学接受手术的患者,MUSIC为多机构登记处,前瞻性追踪人口学、治疗和临床变量。
- 共纳入18050例患者,其中15310例为对照,2740例为前列腺癌病例;病例中位年龄66.1岁(四分位距59.9-71.6),对照中位年龄56.6岁(四分位距42.6-66.7)。
主要发现
- PRS预测前列腺癌发病风险的aAUC范围为0.51(95%CI 0.51-0.53)至0.67(95%CI 0.66-0.68)。
- 根据前列腺活检数据,PRS与疾病侵袭性之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Polygenic risk scores (PRSs) have been developed to identify men with the highest risk of prostate cancer. Our aim was to compare the performance of 16 PRSs in identifying men at risk of developing prostate cancer and then to evaluate the performance of the top-performing PRSs in differentiating individuals at risk of aggressive prostate cancer. METHODS: For this case-control study we downloaded 16 published PRSs from the Polygenic Score Catalog on May 28, 2021 and applied them to Michigan Genomics Initiative (MGI) patients. Cases were matched to the Michigan Urological Surgery Improvement Collaborative (MUSIC) registry to obtain granular clinical and pathological data. MGI prospectively enrolls patients undergoing surgery at the University of Michigan, and MUSIC is a multi-institutional registry that prospectively tracks demographic, treatment, and clinical variables. The predictive performance of each PRS was evaluated using the area under the covariate-adjusted receiver operating characteristic curve (aAUC), and the association between PRS and disease aggressiveness according to prostate biopsy data was measured using logistic regression. KEY FINDINGS AND LIMITATIONS: We included 18 050 patients in the analysis, of whom 15 310 were control subjects and 2740 were prostate cancer cases. The median age was 66.1 yr (interquartile range 59.9-71.6) for cases and 56.6 yr (interquartile range 42.6-66.7) for control subjects. The PRS performance in predicting the risk of developing prostate cancer according to aAUC ranged from 0.51 (95% confidence interval 0.51-0.53) to 0.67 (95% confidence interval 0.66-0.68). By contrast, there was no association between PRS and disease aggressiveness. CONCLUSIONS AND CLINICAL IMPLICATIONS: Prostate cancer PRSs have modest real-world performance in identifying patients at higher risk of developing prostate cancer; however, they are limited in distinguishing patients with indolent versus aggressive disease. PATIENT SUMMARY: Risk scores using data for multiple genes (called polygenic risk scores) can identify men at higher risk of developing prostate cancer. However, these scores need to be refined to be able to identify men with the highest risk for clinically significant prostate cancer.
引用
- Vince RA, Sun H, Singhal U, et al. Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set. Eur Urol Oncol. 2024. PMID: 38734542. doi:10.1016/j.euo.2024.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。